Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
169 results
D2.193 - Oral Induction of Tolerance to Cow's Milk Protein Allergy in Omani Children: A Retrospective Analysis
000140 - Effectiveness of Tezepelumab in uncontrolled severe asthma. ADVANCAT (Advancing severe asthma care with Tezepelumab in Catalonia)
000486 - Objective and Subjective Sleep Assessments in Patients With Atopic Dermatitis Treated With Dupilumab: Results From DUPISTAD, a Phase 4 Randomized Placebo-Controlled Study
100006 - A real-world study of tezepelumab in severe asthmatics of a French cohort
100455 - Ocrelizumab-associated secondary hypogammaglobulinemia and sever pneumonia: Case Report
D1.116 - Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis
D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases
D1.118 - The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience
D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model
D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment
D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab
D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos
D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD
D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)
D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series
D1.376 - Emerging inmunomodulatory agents for atopic dermatitis
D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
D1.379 - AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)
Pagination
First page
First
Previous page
Previous
Page
1
Page
2
Page
3
Page
4
Current page
5
Page
6
Page
7
Page
8
Page
9
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download